Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Health technology save search
QuidelOrtho To Report First Quarter 2024 Financial Results
Published: 2024-04-17 (Crawled : 13:00) - biospace.com/
QDEL | News M | $39.09 2.17% 2.12% 1.1M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: -4.06%
first report financial results
Moderna to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
Published: 2024-04-17 (Crawled : 13:00) - biospace.com/
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: 1.3%
H: 0.0%
C: -1.62%
first report financial results
Repligen to Report First Quarter 2024 Financial ResultsWebcast and Conference Call to Be Held Wednesday, May 1, 2024, at 8:30 a.m. ET
Published: 2024-04-17 (Crawled : 13:00) - biospace.com/
RGEN | $157.12 0.04% 0.04% 380K
|
Health Technology
|
| O: 0.24%
H: 2.41%
C: -2.57%
first conference report financial
Repligen to Report First Quarter 2024 Financial Results
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
RGEN | $157.12 0.04% 0.04% 380K
|
Health Technology
|
| O: 0.24%
H: 2.41%
C: -2.57%
first report financial results
BrainsWay Expands Deep TMS™ Access in Israel Following Significant Increase in Reimbursement Rates
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
BWAY | $4.835 0.94% 0.93% 41K
|
Health Technology
|
| O: -2.88%
H: 0.0%
C: 0.0%
israel
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
WINT | $0.3419 0.62% 0.61% 470K
|
Health Technology
|
| O: -4.17%
H: 0.0%
C: 0.0%
business key therapeutics financial results
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
CLDX | $37.98 -1.43% -1.45% 590K
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: 0.0%
urticaria study
Royalty Pharma Declares Second Quarter 2024 Dividend
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.28%
C: -0.16%
RPRX | News | $28.17 1.0% 0.99% 1.8M
|
Health Technology
|
| O: -1.5%
H: 0.84%
C: 0.25%
pharma royalty
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: -6.87%
H: 0.0%
C: 0.0%
tacti-004 lung positive cancer cell for trial
Bionano and Diagens Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis that Combines OGM and Artificial Intelligence
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
BNGO | $0.75 -4.73% -4.96% 980K
|
Health Technology
|
| O: 1.04%
H: 0.0%
C: 0.0%
partnership first intelligence
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
Published: 2024-04-17 (Crawled : 12:00) - prnewswire.com
NRBO | $3.325 -3.34% -3.46% 21K
|
Health Technology
|
| O: 8.53%
H: 0.0%
C: -6.23%
da-1726 obesity first treatment pharmaceuticals for trial
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
MYGN F | $18.515 0.03% 0.03% 490K
|
Health Technology
|
| O: 1.93%
H: 1.47%
C: -2.05%
health genesight
Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
MIST | $1.64 0.61% 0.61% 30K
|
Health Technology
|
| O: 5.26%
H: 1.11%
C: -2.78%
milestone etripamil symposium pharmaceuticals cardiovascular
KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
KRMD | $2.06 0.0% 59K
|
Health Technology
|
| O: -0.94%
H: 4.29%
C: 0.95%
first report medical financial results
Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.59%
H: 0.0%
C: 0.0%
results
Future Pak Confirms Proposal to Acquire Vanda Pharmaceuticals for $7.25 to $7.75 Per Share in Cash
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
MC | $51.65 1.33% 0.0% 590K
|
Finance
|
| O: 0.56%
H: 0.8%
C: -0.41%
VNDA | $5.11 2.82% 2.74% 2.4M
|
Health Technology
|
| O: 35.5%
H: 4.61%
C: -3.32%
pharmaceuticals acquire for proposal
NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
NBY | $0.0824 -1.91% 0.0% 1.6M
|
Health Technology
|
| O: 38.7%
H: 0.0%
C: -20.0%
sales first revenue care pharmaceuticals for
New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
GENE 1 d | $2.27 -6.97% -7.49% 64K
|
Health Technology
|
| O: 3.47%
H: 0.0%
C: -3.66%
precision treatment
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
SAGE | $13.35 2.42% 2.36% 1.3M
|
Health Technology
|
| O: -15.02%
H: 3.55%
C: -3.01%
sage-718 disease treatment topline parkinson’s therapeutics results study
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
Published: 2024-04-17 (Crawled : 11:00) - prnewswire.com
BLRX | $0.6564 2.55% 2.48% 190K
|
Health Technology
|
| O: -1.16%
H: 0.0%
C: 0.0%
aphexda presentation meeting
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.